Cue Biopharma, Inc. (CUE) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 9 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CUE is $4.33, representing a +888.6% upside from the current price of $0.438. Price targets range from a low of $2.00 to a high of $7.00.
